Comments on: Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC

Comments on: Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC https://www.novumpr.nl/2018/10/19/real-world-study-shows-using-giotrifgilotrif-afatinib-followed-by-osimertinib-provides-a-median-of-27-6-months-of-chemotherapy-free-time-in-patients-with-egfr-mutation-positive-nsclc/?utm_source=rss&utm_medium=rss&utm_campaign=real-world-study-shows-using-giotrifgilotrif-afatinib-followed-by-osimertinib-provides-a-median-of-27-6-months-of-chemotherapy-free-time-in-patients-with-egfr-mutation-positive-nsclc NovumPR press releases Fri, 19 Oct 2018 10:39:15 +0000 hourly 1 https://wordpress.org/?v=6.8.2